Isolated nucleic acid molecule coding for tumor rejection...

Details Isolated nucleic acid molecule coding for tumor rejection... Isolated nucleic acid molecule coding for tumor rejection...

1998-04-24

2002-11-05

Caputa, Anthony C. (Department: 1642)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C536S023100, C530S350000, C435S069100, C435S070100, C435S252300, C435S358000, C435S365000

Reexamination Certificate

active

06475783

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to a nucleic acid molecules which code for tumor rejection antigen precursors. More particularly, the invention concerns nucleic acid molecules which encode tumor rejection antigen precursors which can be processed, inter alia, into peptides presented by many MHC molecules, such as HLA-A1 and its alleles, HLA-A2, HLA-Cw*1601, HLA-B44, and so forth. MAGE-C1, a preferred embodiment, shares partial homology with other members of the MAGE family known to date but is approximately 2 kb larger. MAGE-C2 is another preferred embodiment. These nucleic acid molecules are expressed in a variety of tumors and in normal testis cells, but are not expressed by other normal cells.
BACKGROUND AND PRIOR ART
The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T lymphocyte, or “T cell” response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens (“HLA”), or major histocompatibility complexes (“MHCs”), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al.,
Advanced Immunology
(J. P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cells and HLA/peptide complexes is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See in this regard, Barinaga,
Science
257:880 (1992); Fremont et al.,
Science
257:919 (1992); Matsumura et al.,
Science
257:927 (1992); Latron et al.,
Science
257:964 (1992).
The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992, published on Nov. 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific cytolytic T lymphocytes (“CTLs”). The genes are said to code for “tumor rejection antigen precursors” or “TRAP” molecules, and the peptides derived therefrom are referred to as “tumor rejection antigens” or “TRAs.” See Traversari et al.,
Immunogenetics
35:145 (1992); van der Bruggen et al.,
Science
254:1643 (1991), for further information on this family of genes. Also, see U.S. Pat. No. 5,342,774 and U.S. Pat. No. 5,462,871 incorporated by reference in their entirety.
In U.S. Pat. No. 5,405,940 the disclosure of which is incorporated by reference, it is explained that the MAGE-1 gene codes for a tumor rejection antigen precursor, which is processed to nonapeptides which are presented by the HLA-A1 molecule. The nonapeptides which bind to HLA-A1 follow a “rule” for binding in that a motif is satisfied. In this regard, see, e.g., PCT/US93/07421; Falk et al.,
Nature
351:290-296 (1991); Engelhard,
Ann Rev. Immunol
. 12:181-207 (1994); Ruppert et al.,
Cell
74:929-937 (1993); Rotzschke et al.,
Nature
348:252-254 (1990); Bjorkman et al.,
Nature
329:512-518 (1987); Traversari et al.,
J. Exp. Med
. 176:1453-1457 (1992). The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind to one HLA molecule, but not to others. Because different individuals possess different HLA phenotypes, identification of a particular peptide as being a partner for a particular HLA molecule has diagnostic and therapeutic ramifications, only for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.
In U.S. patent application Ser. No. 288,977, filed Aug. 11, 1994 now U.S. Pat. No. 5,629,166 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-Cw*1601 molecules. The disclosure shows that a given TRAP can yield a plurality of TRAs, each of which will satisfy a motif rule for binding to an MHC molecule.
In U.S. patent application Ser. No. 994,928, filed Dec. 22, 1992, and incorporated by reference herein teaches that tyrosinase, a molecule which is produced by some normal cells (e.g., melanocytes), is processed in tumor cells to yield peptides presented by HLA-A2 molecules.
In U.S. patent application Ser. No. 08/032,978, filed Mar. 18, 1993, and incorporated by reference in its entirety, a second TRA, not derived from tyrosinase is taught to be presented by HLA-A2 molecules. The TRA is derived from a TRAP, but is coded for by a non-MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources.
In U.S. patent application Ser. No. 08/079,110, filed Jun. 17, 1993 now Pat. No. 5,571,711 issued Jan. 5, 1996 and incorporated by reference herein, an unrelated tumor rejection antigen precursor, the so-called “BAGE” precursor is described. The BAGE precursor is not related to the MAGE family.
In U.S. patent applications Ser. No. 08/096,039 and Ser. No. 08/250,162, both of which are incorporated by reference, a non-MAGE TRAP precursor, GAGE, is also disclosed.
U.S. application Ser. No. 08/316,231 filed Sep. 30, 1994, discloses that additional tumor rejection antigen precursors. These tumor rejection antigen precursors are referred to as “DAGE” tumor rejection antigen precursors. They do not show homology to the MAGE, the BAGE, or GAGE family of genes.
The work which is presented by the papers, patent, and patent applications cited supra deals, in large part, with the MAGE, BAGE, GAGE, and DAGE family of genes. The present invention relates to nucleic acid molecules encoding a MAGE-related tumor rejection antigen precursor, i.e., MAGE-C1 and MAGE-C2, and to the tumor rejection antigen precursors and tumor rejection antigens themselves. The invention also relates to applications of both nucleic acid and protein molecules.
The invention is elaborated upon further in the disclosure which follows.


REFERENCES:
patent: 4889806 (1989-12-01), Olson et al.
patent: 9403205 (1994-02-01), None
Sambrook et al, Molecular Cloning, p. 9.47, 1987.*
Acession No. AA581014. Gen Bank, 1995.*
De Plaen et al, Accession No. U10685, GenBank and MPSRCH Scaule Report pp. 3, 4, 15, 16, 1994.*
Harris J Am. Society Neplerology 6: 1125-1133, 1995.*
Ahu et al. Nature Genetics 3(4): 283-91, 1993.*
Cawthon. Genomic 9(3): 446-60, 1991.*
De Plaen Immuno Genetics 40:360-369, 1994.*
Bowie, Science, 257: 1306-1310, 1990*
Burgess, J Cell Biol. 111: 2129-2138, 1990.*
Lazar. Mol. Cells Biol. 8:1247-1252, 1988.*
Bork Gen Res. 10: 398-400, 2000.*
Sambrook. Mol. Cloning, A Lab Manual 2ndEd. Cold Spring Harbor Press, Cold Spring Harbor, pp. 16.3-16.4, 1989.*
Townsend et al., The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined With Short Synthetic Peptides,Cell44:959-968 (1986).
Bjorkman et al., The foreign antigen binding site and T cell recognition regions of claim I histocompatibility antigens,Nature329:512-518 (1987).
Van der Bruggen et al., A Gene Encoding an Antigenic Recognized by Cytolytic T Lymphocytes on a Human Melanoma,Science254:1643-1647 (1991).
Traversari et al., A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E,J. Exp. Med.176:1453-

Affiliated with

Also associated with

Rating

Isolated nucleic acid molecule coding for tumor rejection... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isolated nucleic acid molecule coding for tumor rejection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated nucleic acid molecule coding for tumor rejection... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2916008